Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.
We used cDNA microarrays to evaluate the relative expression of approximately 5,700 human genes in a human multiple myeloma cell line (8226) and its doxorubicin-resistant subline (8226/D40).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback